Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia.[1][2][3][4] One of its metabolites also has some affinity for the H1 receptor.[2] As of May 2018, the drug is in phase III clinical trials.[5]

Clinical data
Other namesMIN-101; CYR-101; MT-210
Routes of
By mouth
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass366.436 g/mol g·mol−1
3D model (JSmol)

See also


  1. Mestre, Tiago A; Zurowski, Mateusz; Fox, Susan H (2013). "5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders". Expert Opinion on Investigational Drugs. 22 (4): 411–421. doi:10.1517/13543784.2013.769957. ISSN 1354-3784.
  2. Ebdrup, Bjørn H; Rasmussen, Hans; Arnt, Jørn; Glenthøj, Birte (2011). "Serotonin 2A receptor antagonists for treatment of schizophrenia". Expert Opinion on Investigational Drugs. 20 (9): 1211–1223. doi:10.1517/13543784.2011.601738. ISSN 1354-3784.
  3. Köster, Luisa-Sophie; Carbon, Maren; Correll, Christoph U (2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–531. doi:10.1517/14728214.2014.958148. ISSN 1472-8214.
  4. "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
  5. "Roluperidone". AdisInsight.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.